

BioPharma Credit PLC (BPCR:LN)



London
Stock Exchange

Financials/Closed End Investments

Price: 1.01 usd

Report Date: August 3, 2020

Business Description and Key Statistics

BioPharma Credit is a closed-ended investment company. Co.'s investment objective is to generate long-term shareholder returns, predominantly in the form of sustainable income distributions from exposure to the life sciences industry. Co. may acquire debt assets directly from the entity issuing debt assets and in the secondary market. Co. may also invest in equity issued by a LifeSci Company, acquired directly from the LifeSci Company or in the secondary market.

Website: www.bpcruk.com
ICB Industry: Financials
ICB Subsector: Closed End Investments
Address: Beaufort House;51 New North Road
 Exeter
 GBR
Employees:

	Current	YTY % Chg
Revenue LFY (M)	147	45.1
Operating EPS LFY	0.07	21.4
Market Value (M)	14	
Shares Outstanding (000)	1,373,932	
Book Value Per Share	1.02	
EBITDA Margin %	83.50	
Net Margin %	49.0	
Long-Term Debt / Capital %	0.0	
Dividends and Yield TTM	0.08 - 819.80%	
Payout Ratio TTM %	100.0	
60-Day Average Volume (000)	1,261	
52-Week High & Low	1.04 - 0.86	
Price / 52-Week High & Low	0.97 - 1.17	

Price, Moving Averages & Volume



BioPharma Credit PLC is currently trading at 1.01 which is 3.1% above its 50 day moving average price of 0.98 and 3.1% above its 200 day moving average price of 0.98.

BPCR:LN is currently 2.9% below its 52-week high price of 1.04 and is 17.4% above its 52-week low price of 0.86. Over the past 52-weeks, BPCR:LN is down 1.9% while on a calendar year-to-date basis it is down 1.0%.

The Relative Strength Index (RSI) indicator for BPCR:LN is currently 59.25. An RSI value of 70 and above is considered overbought and 30 and below oversold.

BioPharma Credit PLC (BPCR:LN)



London
Stock Exchange

Financials/Closed End Investments

Price: 1.01 usd

Report Date: August 3, 2020


Price Performance, Technical Indicators & Risk Metrics

Price Performance	% Change	Difference vs FTSE 350	Technical Indicators	
1-Day %	-0.49	-2.62	50-Day Average Price	0.98
1-Week %	0.50	1.48	Price / 50-Day Average	1.03
4-Week %	2.02	5.75	200-Day Average Price	0.98
52-Week %	-1.94	15.38	Price / 200-Day Average	1.03
Quarter-to-Date %	3.48	5.29	RSI - Relative Strength Index	59.25
Year-to-Date %	-0.98	19.31	Risk Metrics	
Last Month %	4.00	7.86	Price Volatility	0.01
Last Quarter %	9.66	0.14	Sharpe Ratio	-0.05
Last Calendar Year %	-4.23	-18.40	Sortino Ratio	-0.08

5-Year Price Performance vs. FTSE 350

BioPharma Credit PLC
FTSE 350 Index

Current: 0.98 CAGR: -0.5%
Current: 0.83 CAGR: -3.7%



Over the past five years, BioPharma Credit PLC's stock price is down 1.7% which is 15.6% above the FTSE 350 Index performance of -17.3% over the same period. BioPharma Credit PLC's cumulative annualized growth rate (CAGR) over the five year period has been -0.5% while that of the FTSE 350 Index has been -3.7%.

Over the past year, BioPharma Credit PLC's stock price performance of -1.9% has outperformed that of the FTSE 350 Index by 15.4%. On a year-to-date basis, BioPharma Credit PLC's stock price performance of -1.0% has outperformed the FTSE 350 Index by 19.3%.

Over the past week, BioPharma Credit PLC's stock price performance of 0.5% has outperformed that of the FTSE 350 Index by 1.5%.

BioPharma Credit PLC (BPCR:LN)




Financials/Closed End Investments

Price: 1.01 usd


Report Date: August 3, 2020

Growth and Profitability Metrics


Historical Growth	3-Year	5-Year	10-Year	Profitability	Current	5-Year Average	10-Year Average
Revenues %				Gross Margin %			
Revenues Per Share %				EBITDA Margin %	83.5		
EBITDA %				Pre-Tax Margin %	81.1		
Operating EPS %				Net Margin %	49.0		
Free Cash Flow %				Return on Equity %	6.7		
Cash from Operations %				Return on Capital %	5.3		
Book Value %				Return on Assets %	5.2		




BioPharma Credit PLC's cumulative annualized revenue growth rate over the charted period is 98.1%. This compares to revenue growth of 45.1% last fiscal year and cumulative annualized growth of % over the past 3 years.



BioPharma Credit PLC's cumulative annualized EPS growth rate over the charted period is 52.8%. This compares to EPS growth of 21.4% last fiscal year and cumulative annualized growth of % over the past 3 years.



BioPharma Credit PLC's net profit margin last fiscal year of 49.0% is 0.5% above the period's mean net margin of 48.5%. During the charted period, the observed net profit margin high and low were 61.6% and 43.7% respectively.



BioPharma Credit PLC's return on equity of 6.7% is 0.8% above the period's mean return on equity of 5.9%. During the charted period, the observed ROE high and low were 6.7% and 4.9% respectively.

BioPharma Credit PLC (BPCR:LN)




Financials/Closed End Investments

Price: 1.01 usd


Report Date: August 3, 2020

Valuation Metrics


	Current	5-Year Median	10-Year Median		Current	5-Year Median	10-Year Median
Price / EPS TTM	0.2			Earnings Yield %	100.00		
Price / Sales	0.1			Free Cash Flow Yield %			
Price / Operating Cash Flow				Dividend Yield %	819.80		
Price / Book Value	0.0			Enterprise Value / EBITDA	0.1		



BioPharma Credit PLC is trading at 0.15 times its EPS generated during the latest fiscal year. This multiple is below the historically observed median of 0.18, while high and low observations have been 0.35 and 0.13.



BioPharma Credit PLC is trading at a Price to Sales ratio of 0.07 based on sales generated during the latest fiscal year. This ratio is below the historically observed median ratio of 0.08, while high and low observations have been 0.21 and 0.06.



BioPharma Credit PLC is trading at a Price to Book ratio of 0.01 based on book value at the latest fiscal year end. This ratio is equal to the historically observed Price/Book Value ratio of 0.01, while high and low observations have been 0.01 and 0.01.

BioPharma Credit PLC (BPCR:LN)



Financials/Closed End Investments


Price: 1.01 usd

Report Date: August 3, 2020

Dividends Data

Dividends Per Share TTM	0.08	Payout Ratio TTM %	100.00%	Dividend Yield TTM %	819.80%
Rate	Ex Date	Record Date	Payment Date	Currency	Note
0.018	21-05-2020	22-05-2020	19-06-2020	USD	INTERIM DESIGNATED AS INTEREST DISTRIBUTION
0.030	27-02-2020	28-02-2020	27-03-2020	USD	INTERIM DESIGNATED AS INTEREST DISTRIBUTION
0.018	14-11-2019	15-11-2019	17-12-2019	USD	INTERIM DESIGNATED AS INTEREST DISTRIBUTION
0.018	15-08-2019	16-08-2019	20-09-2019	USD	INTERIM DESIGNATED AS INTEREST DISTRIBUTION
0.018	23-05-2019	24-05-2019	21-06-2019	USD	INTERIM DESIGNATED AS INTEREST DISTRIBUTION
0.019	28-02-2019	01-03-2019	29-03-2019	USD	INTERIM USD0.01927441 (USD0.0175 ORD DIV USD0.00177441 SPECIAL) DESIGNATED AS INTEREST...
0.018	01-11-2018	02-11-2018	30-11-2018	USD	INTERIM USD0.0175 DESIGNATED AS INTEREST DISTRIBUTION
0.018	30-08-2018	31-08-2018	28-09-2018	USD	INTERIM USD0.0175 DESIGNATED AS INTEREST DISTRIBUTION
0.013	31-05-2018	01-06-2018	29-06-2018	USD	INTERIM USD0.0134 DESIGNATED AS INTEREST DISTRIBUTION
0.021	08-03-2018	09-03-2018	29-03-2018	USD	INTERIM USD0.02108759 DESIGNATED AS INTEREST DISTRIBUTION. COMPRISES USD0.01 QUARTERLY AN...
0.010	14-12-2017	15-12-2017	31-01-2018	USD	USD0.01, USD0.009938 DESIGNATED AS INTEREST DISTRIBUTION AND USD0.000062 AS ORDINARY...
0.010	28-09-2017	29-09-2017	31-10-2017	USD	INTERIM GROSS

Dividend Growth and Yield



BioPharma Credit PLC's trailing 12-month dividend per share is 0.08 and its dividend has grown at a cumulative annualized rate of 74.2% over the charted period. This compares to dividend growth of 15.40% over the past year and cumulative annualized growth of % over the past 3 years.



BioPharma Credit PLC's current dividend yield is 819.80% based on trailing 12 month dividends. The current yield is above the historically observed median of 653.05% and, over the charted time period, the observed high yield has been 962.79% and the observed low yield has been 189.57%.

BioPharma Credit PLC (BPCR:LN)



London
Stock Exchange

Financials/Closed End Investments

Price: 1.01 usd

Report Date: August 3, 2020

Subsector Peer Comparisons

Market Value (M)

Revenue LFY (M)

Price / EPS TTM

Price / Book Value

EPS 5-Year Growth Rate %

Revenue 5-Year Growth Rate %

BioPharma Credit PLC (BPCR:LN)



London
Stock Exchange

Financials/Closed End Investments

Price: 1.01 usd

Report Date: August 3, 2020

Abbreviations:

CAGR	- Cumulative annual growth rate.
EBIT	- Earnings before interest and taxes.
EBITDA	- Earnings before interest, taxes, depreciation & amortization.
LFY	- Last fiscal year
M	- Million
LON	- London Stock Exchange

Definitions:

Market Value - Weekly Price times latest Shares Outstanding times any applicable ADR factor.

Revenue - Sum of the last four quarters of Revenues.

Revenue Per Share - Sum of the last four quarters of Total Revenue divided by Weighted Average Shares Outstanding.

Operating EPS LFY - EPS excluding non-recurring, non-operating items, fiscal year aligned TTM value.

60-Day Average Volume (000) - The average of the last 60 daily volume values in thousands of shares.

Price 52-Week High - The high closing price from the last 52 weeks of daily closing prices.

Price 52-Week Low - The low closing price from the last 52 weeks of daily closing prices.

Price / 52-Week High - Latest price divided by the high price from the past 52 weeks of daily closing prices.

Price / 52-Week Low - Latest price divided by the low price from the past 52 weeks of daily closing prices.

50-Day Average Price - Mean of last 50 daily closing prices.

200-Day Average Price - Mean of last 200 daily closing prices.

Price / 50-Day Average Price - Latest closing price divided by mean of last 50 daily closing prices, as a percentage.

Price / 200-Day Average Price - Latest closing price divided by mean of last 200 daily closing prices, as a percentage.

Relative Strength Index - Relative Strength Index or RSI measures the magnitude of gains over a given time period against the magnitude of losses over that period. The equation is $RSI = 100 - 100 / (1 + RS)$ where $RS = (\text{total gains} / n) / (\text{total losses} / n)$ and $n = \text{number of RSI periods}$. In this item, 14 days is used and one year of daily prices are considered. A value of 30 or below may imply oversold and 70 or above may imply overbought.

Price Volatility - The standard deviation of the last 20 days of daily closing prices.

Sharpe Ratio - The 5 year average of the excess monthly return over the risk - free rate (1 - month T - bill) over the 5 year standard deviation of the same series.

Sortino Ratio - The same calculation as the Sharpe Ratio but with positive excess returns set to zero for the standard deviation denominator, so only negative volatility weighs in.

Dividends Per Share TTM - Sum of the last four quarters of Dividends Per Share.

Payout Ratio - Dividends Per Share TTM divided by Operating EPS TTM.

Dividend Yield TTM % - Sum of the last four quarter of Dividends Per Share divided by Weekly Price.

EBITDA - Sum of the last four quarters of EBITDA (Operating Income + Depreciation & Amortization).

Free Cash Flow - Sum of the last four quarters Net Cash from Operations minus Capital Expenditures (Purchase of Property, Plant & Equipment), from the Cash Flow Statement.

Book Value - Total Common Equity last quarter divided by Shares Outstanding last quarter.

Book Value Per Share - Total Common Equity last quarter divided by Shares Outstanding last quarter.

Gross Margin % - Sum of the last four quarters Gross Profit divided by the sum of the last four quarters Revenues.

EBITDA Margin % - Sum of the last four quarters EBITDA divided by the sum of the last four quarters Revenues.

Pre-Tax Margin % - Sum of the last four quarters of Earnings Before Taxes divided by sum of the last four quarters Revenues.

Net Profit Margin % - Sum of the last four quarters of Operating EPS divided by sum of the last four quarters Revenues Per Share.

Return on Equity % - Sum of the last four quarters of Operating EPS divided by the average of the last four quarters Book Value.

Return on Capital % - Sum of the last four quarters of Operating EPS divided by the average of the last four quarters Total Capital Per Share.

Return on Assets % - Sum of the last four quarters of Operating EPS divided by the average of the last four quarters Total Assets Per Share.

Price / EPS TTM - Weekly Price divided by the sum of the last four quarters of Operating EPS (capped at 99.9).

Price / Sales - Weekly Price divided by Revenues Per Share TTM.

Price / Book Value - Weekly Price divided by Book Value Per Share last quarter. Book Value Per Share is Total Common Equity last quarter divided by Shares Outstanding last quarter (capped at 49.9).

Free Cash Flow Yield % - Free Cash Flow Per Share TTM divided by Weekly Price.

Enterprise Value - Market Value plus Total Debt last year plus Preferred Equity last year minus Cash & Cash Equivalents last year.

Enterprise Value / Sales - Enterprise Value divided by the sum of the last four quarters of Revenue.

Enterprise Value / EBITDA - Enterprise Value divided by EBITDA TTM.

Enterprise Value / EBIT - Enterprise Value divided by trailing four quarters of Operating Income.

Enterprise Value / Free Cash Flow - Enterprise Value divided by the sum of the last four quarters of Free Cash Flow.

Russell 1000 Index - The largest 1,000 stocks by market cap, the index comprehensively covers the US large cap universe.

EPS 5-Year Growth Rate % is capped at 999.9%.

Revenue 5-Year Growth Rate % is capped at 999.9%.

BioPharma Credit PLC (BPCR:LN)



Financials/Closed End Investments

Price: 1.01 USD

Report Date: August 3, 2020

Disclaimer:

© 2020 London Stock Exchange Group plc and its applicable group undertakings (the "LSE Group"). The LSE Group includes (1) FTSE International Limited ("FTSE"), (2) Frank Russell Company ("Russell"), (3) FTSE Global Debt Capital Markets Inc. and FTSE Global Debt Capital Markets Limited (together, "FTSE Canada"), (4) MTSNext Limited ("MTSNext"), (5) Mergent, Inc. ("Mergent"), (6) FTSE Fixed Income LLC ("FTSE FI") and (7) The Yield Book Inc ("YB"). All rights reserved.

FTSE Russell® is a trading name of FTSE, Russell, FTSE Canada, MTSNext, Mergent, FTSE FI, YB. "FTSE®", "Russell®", "FTSE Russell®", "MTS®", "FTSE4Good®", "ICB®", "Mergent®", "The Yield Book®" and all other trademarks and service marks used herein (whether registered or unregistered) are trademarks and/or service marks owned or licensed by the applicable member of the LSE Group or their respective licensors and are owned, or used under licence, by FTSE, Russell, MTSNext, FTSE Canada, Mergent, FTSE FI, YB. FTSE International Limited is authorised and regulated by the Financial Conduct Authority as a benchmark administrator.

All information is provided for information purposes only. All information and data contained in this publication is obtained by the LSE Group, from sources believed by it to be accurate and reliable. Because of the possibility of human and mechanical error as well as other factors, however, such information and data is provided "as is" without warranty of any kind. No member of the LSE Group nor their respective directors, officers, employees, partners or licensors make any claim, prediction, warranty or representation whatsoever, expressly or impliedly, either as to the accuracy, timeliness, completeness, merchantability of any information or of results to be obtained from the use of FTSE Russell indexes or data or the fitness or suitability of the FTSE Russell indexes or data for any particular purpose to which they might be put. Any representation of historical data accessible through FTSE Russell indexes or data is provided for information purposes only and is not a reliable indicator of future performance.

No responsibility or liability can be accepted by any member of the LSE Group nor their respective directors, officers, employees, partners or licensors for (a) any loss or damage in whole or in part caused by, resulting from, or relating to any error (negligent or otherwise) or other circumstance involved in procuring, collecting, compiling, interpreting, analysing, editing, transcribing, transmitting, communicating or delivering any such information or data or from use of this document or links to this document or (b) any direct, indirect, special, consequential or incidental damages whatsoever, even if any member of the LSE Group is advised in advance of the possibility of such damages, resulting from the use of, or inability to use, such information.

No member of the LSE Group nor their respective directors, officers, employees, partners or licensors provide investment advice and nothing contained in this document or accessible through FTSE Russell indexes or data, including statistical data and industry reports, should be taken as constituting financial or investment advice or a financial promotion.

No part of this information may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the applicable member of the LSE Group. Use and distribution of the LSE Group data requires a licence from FTSE, Russell, FTSE Canada, MTSNext, Mergent, FTSE FI, YB, and/or their respective licensors.